Where to buy 1B-LSD for sale online

The online market for research chemicals has grown exponentially in recent years, offering many substances that often fall into the grey area of legality. Among these substances, 1B-LSD, a designer drug and analog of the well-known hallucinogen LSD, has gained popularity. However, purchasing and using 1B-LSD from online sellers raises significant concerns.
Firstly, the reliability and trustworthiness of these online vendors remain questionable. Many of these sellers operate in legally ambiguous territory, making it challenging to ensure their products’ quality, purity, and safety. Consumers are playing Russian roulette with their health without proper regulation when buying 1B-LSD or any other research chemical online.
Moreover, the marketing tactics employed by these vendors often glamorize these substances, downplaying the potential risks associated with their use. They frequently use misleading terms such as “legal highs” or “research chemicals” to make these substances seem less dangerous than they are. This deceptive advertising can lure unsuspecting buyers into a false sense of security.
The sale of 1B-LSD and similar substances also raises ethical concerns. These chemicals are often sold without adequate warnings about potential health risks, including psychological distress, hallucinations, and even lasting mental health issues. The lack of information and support for individuals who buy and use these substances is deeply troubling.

Summary

1-Butanoyl-d-lysergic acid diethylamide, commonly known as 1B-LSD, belongs to the lysergamide class and is a relatively new addition to psychedelic substances. This compound shares close chemical ties with LSD (lysergic acid diethylamide) and 1P-LSD, yielding nearly identical reported effects. It exerts its influence primarily on the 5-HT2A receptor, much like its counterparts, although it is roughly 14% as potent as LSD regarding its psychoactive effects.
The exact date of 1B-LSD’s initial synthesis remains unknown. Unlike many research chemicals, this substance lacks any documented history within the scientific literature. Reports of its usage began to surface in 2018, coinciding with its emergence in the online research chemical market.
Users describe a range of subjective effects when experimenting with 1B-LSD, including experiences like visual geometry, hallucinatory states, time distortion, heightened introspection, conceptual thinking, increased appreciation for music, euphoria, and ego dissolution. Interestingly, these reported effects closely mirror those of 1P-LSD, suggesting a remarkable similarity between the two substances. Notably, 1B-LSD serves as a prodrug for LSD, implying that their primary distinction likely lies in absorption rates and duration.
Despite its growing popularity, limited data exists concerning the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is generally assumed to carry a risk profile and toxicity akin to LSD, although no conclusive evidence supports this assumption. Consequently, individuals considering using 1B-LSD are strongly encouraged to adopt harm-reduction practices to minimize potential risks associated with its consumption. As with any novel substance, a cautious and informed approach is paramount to ensure personal safety and well-being.
1-Butanoyl-d-lysergic acid diethylamide, commonly known as 1B-LSD, belongs to the lysergamide class and is a relatively new addition to psychedelic substances. This compound shares close chemical ties with LSD (lysergic acid diethylamide) and 1P-LSD, yielding nearly identical reported effects. It exerts its influence primarily on the 5-HT2A receptor, much like its counterparts, although it is roughly 14% as potent as LSD regarding its psychoactive effects.
The exact date of 1B-LSD’s initial synthesis remains unknown. Unlike many research chemicals, this substance lacks any documented history within the scientific literature. Reports of its usage began to surface in 2018, coinciding with its emergence in the online research chemical market.
Users describe a range of subjective effects when experimenting with 1B-LSD, including experiences like visual geometry, hallucinatory states, time distortion, heightened introspection, conceptual thinking, increased appreciation for music, euphoria, and ego dissolution. Interestingly, these reported effects closely mirror those of 1P-LSD, suggesting a remarkable similarity between the two substances. Notably, 1B-LSD serves as a prodrug for LSD, implying that their primary distinction likely lies in absorption rates and duration.
Despite its growing popularity, limited data exists concerning the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is generally assumed to carry a risk profile and toxicity akin to LSD, although no conclusive evidence supports this assumption. Consequently, individuals considering using 1B-LSD are strongly encouraged to adopt harm-reduction practices to minimize potential risks associated with its consumption. As with any novel substance, a cautious and informed approach is paramount to ensure personal safety and well-being.

IUPAC name
CAS Number	2349376-12-9
PubChem CID	145875086
ChemSpider	82827098
UNII	Y6JQX3L6LP
Chemical and physical data
Formula	C24H31N3O2
Molar mass	393.531 g·mol−1

History and culture

1B-LSD debuted on the online research chemical market in August 2016, marking its first appearance in the public domain. The origins of 1B-LSD’s synthesis remain mysterious, with no documented references in academic literature predating its emergence in the research chemical market.
Interestingly, the idea of employing 1-alkylated lysergamide derivatives as a strategy to circumvent controlled substance regulations targeting LSD as a precursor had been envisioned as early as 1988, as indicated in a DEA report: “…a reduction in hallucinogenic activity may become acceptable to the U.S. clandestine chemist when he notes that lysergic acid amide is listed as a Schedule III substance in the CFR; therefore, structurally similar substances of this compound are exempted from the CsA amendment. A lucid argument can be made that lysergic acid N, N-dimethylamide is derived from lysergic acid amide rather than LSD. Carrying this theme to the next logical step, one would then assume that the 1-alkyl and 1-acyl derivatives of the N, N-dimethyl isomer would also not be controlled by the CsA amendment.”
This historical context reveals that utilizing 1-alkylated lysergamide derivatives as a workaround to evade regulatory measures targeting LSD has a longstanding history, laying the groundwork for the emergence of substances like 1B-LSD in contemporary research chemical markets.

Chemistry

1B-LSD belongs to the lysergamide family of molecules, closely resembling LSD, and it derives its name from a butyryl group attached to the nitrogen atom within the polycyclic indole structure found in LSD.
The tetracyclic ergoline structure, a hallmark of ergot alkaloids, characterizes LSD and 1B-LSD. However, in contrast to LSD, 1B-LSD features an additional N1-butyryl group. Alterations to the N1 position are among the most commonly undertaken modifications in the ergoline system. This is due to the relative accessibility of the indole nitrogen in this position, making it amenable to various chemical processes such as alkylations, acylations, Mannich reactions, and Michael additions.

Pharmacology

Given its structural resemblance to LSD, 1B-LSD is presumed to act as a partial agonist at the 5-HT2A receptor. The psychedelic effects attributed to 1B-LSD are believed to mainly stem from its interaction with the 5-HT2A receptors dispersed throughout the brain. Additionally, 1B-LSD likely exhibits binding activity at a broad spectrum of monoamine receptors, including those associated with dopamine and norepinephrine. However, it’s important to note that no empirical data exists to substantiate these assertions.
Research has indicated that 1B-LSD, along with its acyl homologs 1P-LSD and ALD-52, undergoes deacylation in the body through processes involving CYP1A2 and CYP3A4 enzymes. This transformation converts 1B-LSD into LSD by eliminating the butyric acid component. These findings have been demonstrated in human blood serum and rodent models.

Subjective effects

1B-LSD, often reported to be nearly indistinguishable from its better-known counterpart LSD, shares a host of subjective effects. These effects, documented based on anecdotal user reports and the analyses of PsychonautWiki contributors, should be considered with a degree of skepticism:

Physical:

1. Stimulation: 1B-LSD typically energizes users without feeling forced, encouraging activities like running, walking, or dancing. This is notably different from other sedating psychedelics like psilocybin.
2. Spontaneous Bodily Sensations: Users often experience intense, euphoric, tingling sensations that can be location-specific or appear unpredictably throughout the trip.
3. Physical Euphoria: While not as reliably induced as with stimulants or entactogens, some users may feel extreme physical comfort and pleasure.
4. Tactile Enhancement: Enhanced tactile sensations are consistently present at moderate levels during 1B-LSD experiences.
5. Stamina Enhancement: Compared to traditional stimulants, stamina enhancement is mild.
6. Appetite Suppression
7. Bodily Control Enhancement
8. Difficulty Urinating
9. Excessive Yawning: Less pronounced than with other substances like psilocybin.
10. Nausea: Occasional mild nausea may occur, typically subsiding after vomiting or as the peak sets.
11. Increased Blood Pressure (citation needed)
12. Increased Heart Rate (citation needed)
13. Increased Perspiration
14. Muscle Contractions
15. Muscle Spasms
16. Pupil Dilation
17. Increased Salivation
18. Vasoconstriction: This may lead to feeling cold, especially in extremities.
19. Seizure: Although largely extrapolated from LSD-induced seizures, it’s a potential risk in those predisposed to them, especially under taxing conditions like dehydration, fatigue, or overheating.

Visual:

1. Enhancements: Brighter colors compared to other psychedelics.
2. Pattern Recognition Enhancement
3. Visual Acuity Enhancement

Distortions:

1. Drifting: Objects may appear to melt, breathe, morph, or flow.
2. Colour Shifting
3. Color Tinting
4. Tracers
5. After Images
6. Depth Perception Distortions
7. Perspective Distortions
8. Recursion
9. Symmetrical Texture Repetition
10. Scenery Slicing

Geometry:

1. Visual geometry is similar to 2C-B or 2C-I, characterized by intricate, algorithmic patterns, bright colors, and sharp edges. At higher levels, it can reach 8B Geometry.

Hallucinatory States:

1. 1B-LSD can induce hallucinatory states less consistently and reproducibly than other psychedelics like DMT or psilocybin. These states include transformations, machine scapes, and internal/external hallucinations.

Cognitive:

1. Analysis Enhancement: Promotes introspection and analysis.
2. Anxiety and paranoia: Less common at lower doses, more likely with cannabis use.
3. Conceptual Thinking
4. Creativity Enhancement
5. Emotion Enhancement
6. Novelty Enhancement
7. Personal Bias Suppression
8. Personal Meaning Enhancement
9. Focus Enhancement: Experienced at low doses.
10. Immersion Enhancement
11. Suggestibility Enhancement
12. Cognitive Euphoria: Less consistent and pronounced than other substances like psilocybin and MDMA.
13. Delusion
14. Déjà Vu
15. Ego Replacement
16. Increased Libido
17. Increased Music Appreciation
18. Increased Sense of Humor: This may lead to uncontrollable laughter fits, especially during the come-up.
19. Memory Suppression
20. Ego Death
21. Multiple Thought Streams
22. Personality Regression
23. Thought Acceleration
24. Thought Disorganization
25. Thought Loops
26. Time Distortion
27. Wakefulness

Auditory:

1. Auditory Enhancement
2. Auditory Distortion
3. Auditory Hallucinations

Multi-Sensory:

1. Synaesthesia: Rare and non-reproducible in its most whole form.

Transpersonal:

1. Spirituality Enhancement
2. Existential Self-Realization
3. Unity and Interconnectedness

Combination:

1. Alcohol: Can reduce anxiety but may lead to adverse outcomes due to dehydration and fatigue.
2. Benzodiazepines: Effective at reducing 1B-LSD’s effects through brain activity suppression.
3. Cannabis: Strongly intensifies sensory and cognitive effects but can increase the risk of adverse psychological reactions.
4. Dissociatives: Enhance cognitive, visual, and hallucinatory effects but may also increase confusion and delusions.
5. MDMA: Highly synergistic, enhancing physical, cognitive, and visual effects. However, it requires cautious dosing. Some evidence suggests increased neurotoxicity with LSD, which may apply to 1B-LSD as well.

Toxicity

The safety profile and long-term health effects of recreational 1B-LSD use remain largely unexplored due to its status as a research chemical with limited human history.

Anecdotal reports suggest that trying 1B-LSD by itself, at low to moderate doses, and infrequently, appears to be associated with minimal adverse health effects. However, it’s crucial to recognize that nothing can be guaranteed entirely in substance use. Therefore, independent research is essential to confirm the safety of combining two or more substances before consumption.

Considering its structural similarity to LSD, 1B-LSD is assumed to be physiologically well-tolerated, with an extremely low toxicity relative to dose. There have been few reported physical side effects following acute 1B-LSD exposure.

Nonetheless, like LSD and other psychedelics, it is plausible that 1B-LSD can act as a trigger for individuals with underlying mental disorders. Those with personal or family histories of mental illness are generally advised to avoid this substance, particularly outside of a supervised medical setting.

Practicing harm reduction strategies is strongly recommended when using 1B-LSD.

Overdose: 

1B-LSD does not have a known toxic dose, but higher doses increase the risk of adverse psychological reactions such as anxiety, delusions, panic attacks, and, rarely, seizures. Medical attention is typically unnecessary unless severe psychotic episodes occur or if fake acid (e.g., 25i-NBOMe or DOB) is ingested. The administration of benzodiazepines or antipsychotics can help alleviate the acute adverse cognitive effects of 1B-LSD.

Dependence and Abuse Potential: 

Although no formal studies have been conducted, it is assumed that, like LSD, 1B-LSD is non-addictive with low abuse potential. There are no reports of successful attempts to train animals to self-administer LSD, which suggests it lacks the necessary pharmacology for dependence. Additionally, there is virtually no withdrawal syndrome upon discontinuation of chronic LSD use, and it is assumed 1B-LSD shares these properties.

Tolerance to 1B-LSD develops almost immediately after ingestion. It takes about 5-7 days for the tolerance to reduce to half and approximately 14 days to return to baseline without further consumption. Cross-tolerance is also observed with other psychedelics, reducing their effects after 1B-LSD use.

Dangerous Interactions: 

Many psychoactive substances that are safe on their own can become dangerous when combined with others. It’s crucial to conduct independent research to ensure the safety of any combination.

1B-LSD may share a similar dangerous interaction profile as LSD. Known risky interactions include:

• Lithium: Combining lithium with psychedelics like 1B-LSD increases the risk of psychosis and seizures, and this combination is discouraged.
• Cannabis: There may be a strong and unpredictable synergy between cannabis and 1B-LSD, potentially leading to adverse psychological reactions such as anxiety, paranoia, panic attacks, and psychosis. Users should be cautious, start with a reduced cannabis dose, and take extended breaks between hits.
• Stimulants: Stimulants like amphetamine, cocaine, or methylphenidate can heighten anxiety, paranoia, panic attacks, and thought loops when combined with 1B-LSD. There may also be an increased risk of mania and psychosis.
• Tramadol: Tramadol is known to lower the seizure threshold, and psychedelics like 1B-LSD may trigger seizures in susceptible individuals.

Legal status

Internationally, the legal status of 1B-LSD varies, often existing in a legal grey area. While it may not be explicitly illegal in some countries, individuals could face charges for its possession under specific circumstances, such as analog laws, or with the intent to sell or consume.

Here is a summary of the legal status of 1B-LSD in several countries:

• Austria: 1B-LSD is not technically illegal, but it may be subject to the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analog of LSD, making it illegal for supply for human consumption.
• Germany: As of July 18, 2019, 1B-LSD is controlled under the New Psychoactive Substances Act (NpSG). Production, import for marketing, administration to others, and trading are punishable. Possession is illegal but not penalized.
• Japan: 1B-LSD is illegal in Japan under the Pharmaceutical Affairs Law, making possession or sale illegal.
• Latvia: Although not officially scheduled, 1B-LSD is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
• Lithuania: 1B-LSD is illegal in Lithuania and has been specifically listed as an illegal substance since June 5, 2019.
• Singapore: 1B-LSD is classified as a Class A controlled substance in Singapore.
• Sweden: After being sold as a designer drug, 1B-LSD was made illegal in Sweden on January 26, 2016.
• Switzerland: 1B-LSD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial purposes.
• United Kingdom: 1B-LSD is illegal to produce, supply, or import in the United Kingdom under the Psychoactive Substance Act, effective from May 26, 2016.
• United States: While not explicitly prohibited by law, 1B-LSD is a prodrug for LSD, which means its possession and sale may be prosecutable in the United States under the Federal Analogue Act.

FAQ

1. What is 1B-LSD? 

1B-LSD, or 1-Butanoyl-d-lysergic acid diethylamide, is a novel psychedelic substance in the lysergamide class. It shares structural similarities with LSD (lysergic acid diethylamide) and 1P-LSD.

2. How does 1B-LSD compare to LSD? 

1B-LSD is closely related to LSD and is reported to produce near-identical effects. However, it’s generally considered about 14% as potent as LSD. It acts as a prodrug for LSD, meaning it converts to LSD in the body.

3. What are the effects of 1B-LSD? 

Users have reported various effects, including visual geometry, hallucinatory states, time distortion, enhanced introspection, conceptual thinking, increased music appreciation, euphoria, and ego loss. The effects are often similar to those of 1P-LSD.

4. Is 1B-LSD safe to use? 

The safety of 1B-LSD is not well-studied, and it exists in a legal grey area in many countries. As with any psychedelic substance, it should be used with caution. Those with underlying mental health issues or a family history of such issues are generally advised against using it.

5. Are there any risks associated with 1B-LSD? 

Like LSD and other psychedelics, 1B-LSD can potentially trigger adverse psychological reactions such as anxiety, delusions, or panic attacks, especially at higher doses. It may also pose risks of seizures, though this is rare. Fake acid substances can be dangerous if ingested mistakenly.

6. Is 1B-LSD addictive? 

No evidence suggests that 1B-LSD is addictive or has a high abuse potential. Tolerance to its effects builds quickly, producing cross-tolerance with other psychedelics.

7. What is the legal status of 1B-LSD? 

The legal status of 1B-LSD varies by country. It’s not specifically illegal in some places but may be subject to analog or controlled substance laws. Always research and understand the laws in your jurisdiction.

8. Can 1B-LSD be used for therapeutic purposes? 

There is limited research on the therapeutic potential of 1B-LSD. Some users have reported positive experiences related to introspection and personal growth, but more research is needed to determine its therapeutic value.

9. How should I use 1B-LSD safely? 

If you choose to use 1B-LSD, harm reduction practices are essential. Start with a low dose, have a sober and trusted trip sitter present, and create a safe and comfortable environment. Avoid combining it with other substances, especially alcohol or cannabis, without careful consideration.

References

1. Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Dowling, G., Wallach, J., Halberstadt, A. L. (August 2019). “Return of the lysergamides. Part V: Analytical and behavioral characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD)”. Drug Testing and Analysis. 11 (8): 1122–1133. doi:10.1002/dta.2613. ISSN 1942-7603.
2. Wagmann, L., Richter, L. H. J., Kehl, T., Wack, F., Bergstrand, M. P., Brandt, S. D., Stratford, A., Maurer, H. H., Meyer, M. R. (July 2019). “In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures.” Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. doi:10.1007/s00216-018-1558-9. ISSN 1618-2642.
3. “1B-LSD (Google Trends)”. Retrieved January 1, 2020.
4. Brandt, S. D.; Kavanagh, P. V.; Westphal, F.; Stratford, A.; Elliott, S. P.; Hoang, K.; Wallach, J.; Halberstadt, A. L. (2015). “Return of the lysergamides. Part I: Analytical and behavioral characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD)”. Drug Testing and Analysis. 8 (9): 891–902. doi:10.1002/dta.1884. ISSN 1942-7603.
5. Cooper, Donald A. (1988). “Future Synthetic Drugs of Abuse”. Proceedings of the international symposium on the forensic aspects of controlled substances. p. 79. ISBN 978-0-93211-509-6.
6. Wagmann, L.; Richter, L. H. J.; Kehl, T.; Wack, F.; Pettersson Bergstrand, M.; Brandt, S. D.; Stratford, A.; Maurer, H. H.; Meyer, M. R. (2019). “In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures.” Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. doi:10.1007/s00216-018-1558-9. ISSN 1618-2642.
7. Armstrong, B. D.; Paik, E.; Chhith, S.; Lelievre, V.; Waschek, J. A.; Howard, S. G. (2004). “Potentiation of (DL)‐3,4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptor partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939”. Neuroscience Research Communications. 35 (2): 83–95. doi:10.1002/nrc.20023. ISSN 1520-6769.
8. Gudelsky, Gary A.; Yamamoto, Bryan; Nash, J. Frank (1994). “Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists”. European Journal of Pharmacology. 264 (3): 325–330. doi:10.1016/0014-2999(94)90669-6. ISSN 0014-2999.
9. Capela, J. P.; Fernandes, E.; Remião, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. (2007). “Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons”. Neurotoxicology. 28 (4): 868–875. doi:10.1016/j.neuro.2007.04.005. ISSN 0161-813X. PMID 17572501.
10. Nichols, David E. (2004). “Hallucinogens”. Pharmacology & Therapeutics. 101 (2): 131–181. doi:10.1016/j.pharmthera.2003.11.002. ISSN 0163-7258.
11. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). “Dose-independent occurrence of seizure with tramadol.” Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
12. “Synthetische Drogen: Neues Gesetz soll “Legal Highs” bekämpfen” [Synthetic drugs: New law is to combat legal highs] (in German). Der Standard. September 28, 2011. Retrieved January 1, 2020.
13. “Entwurf: Bundesgesetz, mit dem ein Bundesgesetz über den Schutz vor Gesundheitsgefahren im Zusammenhang mit Neuen Psychoaktiven Substanzen (Neue-Psychoaktive-Substanzen-Gesetz, NPSG) erlassen und das Suchtmittelgesetz (SMG) geändert wird” (PDF) (in German). Retrieved January 1, 2020.
14. “Anlage NpSG” (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
15. “Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes” (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
16. “§ 4 NpSG” (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
17. “指定薬物を指定する省令が公布されました” (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. They were retrieved on March 25, 2021.
18. “Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem” (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
19. “LR SAM Įsakymas Dėl Narkotinių ir psichotropinių medžiagų sąrašų patvirtinimo” (in Lithuanian). Retrieved January 1, 2020.
20. “Misuse of Drugs Act: (CHAPTER 185)”. sso.agc.gov.sg. March 31, 2008. Retrieved October 22, 2020.
21. “31 nya substanser klassas som narkotika eller hälsofarlig vara” (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. January 26, 2016. Retrieved January 1, 2020.
22. “Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien” (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
23. “Psychoactive Substances Act 2016”. U.K. Government. Retrieved January 1, 2020.
24. 21 U.S. Code § 813 – Treatment of controlled substance analogs.